These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25058005)

  • 1. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.
    Shen H; Zhu F; Liu J; Xu T; Pei D; Wang R; Qian Y; Li Q; Wang L; Shi Z; Zheng J; Chen Q; Jiang B; Shu Y
    PLoS One; 2014; 9(7):e103305. PubMed ID: 25058005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
    Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
    Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer and promotes cell proliferation and invasion via phosphatase and tensin homolog.
    Bi M; Chen W; Yu H; Wang J; Ding F; Tang DJ; Tang C
    Biochem Biophys Res Commun; 2016 Nov; 480(3):369-374. PubMed ID: 27769862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
    Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
    Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q; Wang Y; He J
    J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer.
    Zhang Y; Qian J; Fu Y; Wang Z; Hu W; Zhang J; Wang Y; Guo Y; Chen W; Zhang Y; Wang X; Xie Z; Ye H; Ye F; Zuo Z
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167447. PubMed ID: 39089636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer.
    Sun H; Zhou X; Bao Y; Xiong G; Cui Y; Zhou H
    Open Biol; 2019 Jul; 9(7):180227. PubMed ID: 31337279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
    Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
    Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing.
    Liu J; Wang W; Wang K; Liu W; Zhao Y; Han X; Wang L; Jiang BH
    J Transl Med; 2024 Aug; 22(1):793. PubMed ID: 39198847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.
    Takeda H; Takigawa N; Ohashi K; Minami D; Kataoka I; Ichihara E; Ochi N; Tanimoto M; Kiura K
    Exp Cell Res; 2013 Feb; 319(4):417-23. PubMed ID: 23274758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
    Sudo M; Chin TM; Mori S; Doan NB; Said JW; Akashi M; Koeffler HP
    Cancer Chemother Pharmacol; 2013 May; 71(5):1325-34. PubMed ID: 23515752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
    Wang L; Dong X; Ren Y; Luo J; Liu P; Su D; Yang X
    Cell Death Dis; 2018 Jan; 9(2):129. PubMed ID: 29374157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
    Zhou YM; Liu J; Sun W
    Asian Pac J Cancer Prev; 2014; 15(3):1391-6. PubMed ID: 24606471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
    Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H
    Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.